BRCA1 and breast carcinoma: Regarding PARPi pharmacology, olaparib resistance mediated by the overexpression of transporter protein genes (such as the transmembrane pump PgP or ABCB1) has been described in murine models of breast cancer associated with BRCA1 mutations [7].